Compare · RapidAI

RapidAI alternative and competitors compared, including RapidAI vs Viz.ai

The short answer

RapidAI is a clinical AI platform built for the acute neurovascular pathway. It grew out of CT perfusion analysis for stroke and now runs a module set that flags suspected large vessel occlusion, intracranial hemorrhage, aneurysm and related findings, then routes them to the stroke team. Alternatives to it split into two groups. The first is other acute pathway platforms, where Viz.ai and Aidoc are the names that come up most. The second is whole-read assistants that cover the routine studies a stroke tool never looks at. Radiological.ai is the second kind: it flags suspected findings, prioritizes the worklist and drafts the structured report across X-ray, CT and MRI in one pane. It is decision support, and the radiologist reviews, edits and signs every study.

RapidAI is very good at the job it was built for. The company started in 2011 as iSchemaView, and CT perfusion for acute stroke is still the historical center of the product: the maps that tell an interventionalist whether there is salvageable tissue worth going after. Around that core it has added modules for suspected large vessel occlusion, intracranial hemorrhage, aneurysm, edema and, in November 2025, five more clearances covering DeltaFuse, LMVO, midline shift, obstructive hydrocephalus and aortic measurement. RapidAI says the platform now runs in more than 2,500 hospitals across more than 100 countries. If your problem is the stroke pathway, that is a serious answer to it.

The reason groups start shopping is almost never that the stroke modules underperform. It is scope. A neurovascular platform earns its money on a small slice of the volume, and the rest of the shift, the ankle films and the follow-up chest CTs and the sixty reports still waiting to be dictated at four in the afternoon, sits outside it entirely. Practices that already own a triage tool tend to describe the same gap: the urgent cases get help, and the other ninety percent of the list gets none.

Radiological.ai is built for that other ninety percent. It flags suspected findings for your review, prioritizes the worklist so time-critical studies surface first, and drafts the structured report into your template before you sit down, across X-ray, CT and MRI. It is not a stroke pathway product and it will not replace a dedicated neurovascular platform in a comprehensive stroke center. It is the assistant for the whole reading list, and it is decision support: every flag is a prompt to look, every report is a draft, and you review, edit and sign.

Last updated July 2026

The Reading Station

Assistant ready

Worklist

SERIES 1 · AX

SLICE 24/64

SAMPLE STUDY

NOT FOR DIAGNOSTIC USE

W 80 · L 40

Structured report

Draft

Run the assistant to draft this report for review.

You review & sign

Illustrative sample · not a real patient study, not a diagnosis

Drafted in · you review & sign Worklist re-prioritized

Decision support for qualified clinicians. Radiological.ai does not provide a diagnosis and is not a substitute for professional judgment.

See the comparison

Flag · prioritize · draft · you review and sign

RapidAI is a deep acute neurovascular platform; Radiological.ai is the whole-read assistant that flags, prioritizes and drafts across X-ray, CT and MRI, which is why some groups run one, some run the other, and some run both.

Side by side

RapidAI vs Viz.ai, side by side

The two names that come up whenever a stroke program shortlists. Neither column is the sales column; both are compiled the same way.

What changes	RapidAI	Viz.ai
Where the product started	Founded in 2011 as iSchemaView around CT perfusion analysis. The perfusion maps that estimate core and penumbra are the historical core of the platform.	Founded around care coordination. The first product pushed a suspected LVO alert to the interventionalist phone, and that mobile notification layer is still the center of gravity.
Regulatory milestone	Clears modules through the 510(k) pathway. RapidAI describes Rapid NCCT Stroke as the first FDA clearance of a non-contrast CT product to flag suspected ICH and LVO together.	Received the FDA De Novo authorization in February 2018 for LVO triage, which created the computer-aided triage and notification classification that later products, including competitors, now clear into.
Module breadth in 2026	Perfusion, LVO, ICH, aneurysm, edema and hyperdensity, plus five modules cleared in November 2025: DeltaFuse, LMVO, midline shift, obstructive hydrocephalus and aortic measurement.	Expanded well past stroke into ICH, aneurysm, pulmonary embolism, aortic disease and cardiac workflows, some built with partners such as Avicenna.AI.
Published head-to-head evidence	AJNR, July 2024, 129 acute ischemic stroke patients with 108 studies of adequate quality. Rapid and Viz.ai perfusion outputs correlated, with a rank correlation of 0.82 for Tmax above 6 seconds.	Same study: Viz.ai predicted significantly higher ischemic core volumes at CBF below 30 percent (P below .001). Mean absolute differences were 32.36 mL for Tmax above 6 seconds and 9.5 mL for CBF below 30 percent.
Did those differences change the decision	No. Applying DAWN and DEFUSE 3 eligibility criteria, thrombectomy triage did not differ significantly between the packages (McNemar P = 1.00).	No, same result. The authors still caution that the absolute volumes are not interchangeable, so a site should not mix packages inside one pathway and compare numbers across them.
Vendor-reported performance	Publishes per-module figures, for example 97 percent sensitivity and 96 percent specificity for Rapid LVO.	Publishes per-module figures and maintains a public clinical publications library covering deployments and outcome studies.
Deployment shape	Rapid Edge Cloud, a cloud-first platform with on-premises capability, plus Rapid Navigator and mobile and web applications.	Cloud service with a mobile application as the primary alerting surface for the on-call team.
Published pricing	None. Quoted per site, usually as an annual subscription scoped by module and volume.	None. Same commercial pattern.
Best suited for	Comprehensive stroke centers and neuro programs that want depth in perfusion and a broad neurovascular module set under one vendor.	Networks where the bottleneck is coordination between the reader, the interventionalist and the transferring hospital rather than the imaging analysis itself.

Compiled July 2026 from vendor materials, FDA announcements and the peer-reviewed comparison published in AJNR. Module lists and clearances change quickly in this category, so confirm the current state with each vendor before you build a shortlist around this table.

Side by side

Radiological.ai vs RapidAI, honestly

A fair look at what each does well. Both are capable tools. Here is where they differ.

What matters	Radiological.ai	RapidAI
What the tool covers	Flags suspected findings, prioritizes the worklist and drafts the structured report in one pane	Acute neurovascular pathway: suspected LVO, ICH, aneurysm and related findings, with perfusion analysis underneath
Studies it touches	X-ray, CT and MRI across the general reading list, including the routine volume	The head and vascular studies its cleared modules cover, plus the aortic module
Worklist prioritization	Suspected time-critical studies surface to the top of the general queue for your review	Strong, within the stroke pathway, with alerting built for the interventional team
Structured report drafting	Drafts the report into your template before you sit down, for you to edit and sign	Not a reporting product; the report is still written in your dictation system
Deployment	Cloud, connected to your PACS over standard DICOM	Cloud-first with on-premises capability, integrated across PACS, EHR and reporting systems
Pricing transparency	Per-radiologist plans published on our pricing page	Quoted per site by module and volume; no public list price
Regulatory status	Decision support; we make no regulatory-status claims on this site	A long list of FDA clearances across the neurovascular module set, which is a genuine strength and worth verifying per module

Comparison reflects general, publicly understood positioning. Capabilities change, so check each product for the latest.

If the stroke pathway is genuinely the problem you are solving, read our AI stroke triage software page rather than this one, and compare it against Viz.ai and Aidoc too, since those three are the usual shortlist. Groups whose acute problem is the CTPA queue instead should start at AI pulmonary embolism detection.

If the problem is the whole list rather than one pathway, the mechanics live on our radiology worklist software and structured radiology reporting pages, and the category overview is at best AI radiology software. Before you sign anything, our guide to what FDA clearance does and does not tell you covers how to read a vendor clearance list, and the questions worth asking a radiology AI vendor covers the rest of the diligence.

Why groups pick Radiological.ai

One assistant across the whole read

The other ninety percent of the list

A neurovascular platform is idle on a wrist series, a screening mammogram and a follow-up abdominal CT. Those studies are most of the day. Radiological.ai works the whole queue: it flags suspected findings on X-ray, CT and MRI, orders the list so urgent work surfaces first, and hands you a draft report on studies a stroke tool never opens.

One pane instead of another alert channel

Every additional point tool adds a place to look. Groups running three vendors end up with three alert surfaces, three logins and three support contracts, which is how alert fatigue starts. Consolidating the routine work into a single assistant reduces the number of things competing for attention during a read rather than adding to them.

Decision support, you always sign

Nothing here confirms, rules out or diagnoses. A flag is a prompt to look, a priority is a suggestion about reading order, and a drafted report is a starting point you edit. We publish no accuracy figures and claim no regulatory status on this site. The responsible radiologist reviews and signs every study, the same as today.

Good questions

RapidAI vs Radiological.ai, answered

RapidAI is used for the acute neurovascular pathway, primarily stroke. It analyzes head CT, CT angiography and CT perfusion as studies arrive, flags the ones that appear to show a large vessel occlusion, intracranial hemorrhage or aneurysm, produces perfusion maps estimating core and penumbra, and notifies the stroke team so transfer and treatment decisions start sooner. It changes reading order and speeds notification within that pathway.

Viz.ai and Aidoc are the two most common head-to-head comparisons, with Brainomix and Avicenna.AI also appearing on stroke shortlists. Those are all acute pathway platforms. The other kind of competitor is a whole-read assistant such as Radiological.ai, which does not compete on perfusion depth and instead covers the routine studies and the report drafting that a neurovascular platform does not touch.

RapidAI grew out of CT perfusion analysis and leads with imaging depth; Viz.ai grew out of care coordination and leads with the mobile alert that reaches the interventionalist. Both now cover overlapping module sets. The one published head-to-head comparison, in AJNR in July 2024, found their perfusion volumes correlated but were measurably different, while thrombectomy triage decisions under DAWN and DEFUSE 3 criteria came out the same.

RapidAI modules are FDA cleared, which is not the same thing as approved. Almost all radiology AI reaches the US market through the 510(k) pathway by showing substantial equivalence to a predicate device, or through De Novo when no predicate exists. Clearance says the device is reasonably safe and effective for a stated intended use. It does not say the product will perform the same way on your scanners, your protocols and your patient mix.

RapidAI does not publish list pricing, and neither does anyone else in acute imaging AI. Expect an annual subscription scoped by site, module count and study volume, quoted after a scoping call. The number worth pinning down is the fully loaded first-year total, including integration, any on-premises hardware and training, and then what the subscription does at the third renewal once the tool is embedded in a stroke pathway you cannot easily unplug.

It is if your problem is the whole reading list rather than the stroke pathway specifically. Radiological.ai flags suspected findings, prioritizes the worklist and drafts the structured report across X-ray, CT and MRI, which covers the routine volume a neurovascular platform ignores. It is not a substitute for a dedicated perfusion product in a comprehensive stroke center, and we would rather say so than pretend otherwise.

Plenty of groups run both, and that is a reasonable answer when a comprehensive stroke center needs perfusion depth and the same radiologists still read a general list all day. The question to settle first is where your time actually goes. If thrombectomy cases are a handful a week and the backlog is routine CT and radiography, a second stroke tool will not move the number that hurts.

Four things. What the exact cleared indication says, module by module, in the FDA database rather than the brochure. What the false positive rate looked like at sites with your scanner mix, since alert fatigue is what kills these deployments. Who owns local performance monitoring after go-live, and what report you get. And what the renewal price looks like in year three, in writing, before the pathway depends on it.

More comparisons

See how Radiological.ai compares

vs Aidoc

Aidoc alternative

One assistant across the whole read, not acute triage alone.

vs Rad AI

Rad AI alternative

Drafting plus flagging and triage, in one assistant.

vs Annalise.ai

Annalise.ai alternative

Finding flags plus triage and drafting, together.

vs Nuance PowerScribe

Nuance PowerScribe alternative

More than dictation: flagging, triage and drafting.

vs Qure.ai

Qure.ai alternative

Flags plus triage and drafting, in one assistant.

vs Viz.ai

Viz.ai alternative

Beyond acute stroke triage, across the whole read.

vs Nuance DAX

Nuance DAX alternative

Built for the read, not for the patient conversation.

vs Lunit

Lunit alternative

One assistant across the whole read, not detection on two modalities.

vs Gleamer

Gleamer alternative

One assistant across X-ray, CT and MRI, not a suite of per-exam detectors.

vs PowerScribe One

PowerScribe One vs 360

What actually changes in the cloud move, and the third option.

vs Sirona Medical

Sirona Medical alternative

Add the assistant to the PACS you already run, without replacing the stack.

See every radiology use case

From the blog: what the PowerScribe 360 end of life means for radiology groups, how much radiology AI costs, and the full comparison of the best AI radiology software in 2026.

See how Radiological.ai reads alongside your group

One assistant that flags suspected findings, prioritizes the worklist, and drafts the structured report on X-ray, CT and MRI. You review and sign every study.

See pricing

Decision support for qualified clinicians. Radiological.ai does not provide a diagnosis and is not a substitute for professional medical judgment.